Fundz

Nilogen Oncosystems Announces New Chief Scientific Officer

PRIVATESep 15, 2023

Position

Chief Scientific Officer

Company

Nilogen Oncosystems

Rikhia Chakraborty
rikhiac@nilogen.com
TampaBiotechnologyHealth CareArtificial Intelligence

Description

Nilogen Oncosystems, a privately-held biotechnology company dedicated to increasing efficiency and reducing risk in the oncology drug development process, has announced the appointment of its Vice President of Research and Operations, Rikhia Chakraborty, Ph.D., to Chief Scientific Officer. As Chief Scientific Officer, Dr. Chakraborty will handle internal and external communication to aid in the expansion of Nilogen Oncosystems' mission to significantly improve the rate of success for novel oncology therapies in the clinic by utilizing Nilogen's proprietary 3D models of patients' tumors to perform complex immuno-oncology studies. Dr. Chakraborty's appointment comes after the sudden passing of Dr

Other recent leadership changes in Biotechnology and Health Care

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Nilogen Oncosystems, and when

A new leader at Nilogen Oncosystems brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Nilogen Oncosystems raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Nilogen Oncosystems, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Nilogen Oncosystems. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Nilogen Oncosystems

Location

Tampa, Florida, United States

About

Nilogen Oncosystems is dedicated to streamlining and improving drug development in cancer and immuno-oncology. At Nilogen, we appreciate the complexity of cancer and use fresh patient tumor samples with intact tumor immune microenvironment in our preclinical drug testing platforms. This allows us to see the whole picture for a better understanding of the molecular mechanisms of drug sensitivity and resistance. These proprietary and innovative platforms aim to significantly reduce the cost and risk associated with clinical trials. Nilogen’s commitment to testing and customizing cancer drug development is proven and yields unparalleled results for its clients.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Nilogen Oncosystems changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Rikhia
Likely contact at this company
••••••••@••••••••

See Rikhia's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Nilogen Oncosystems's next move

Learn about Strategic plan

Nilogen Oncosystems changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.